TriangleNCT02511106 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- limitations And Caveats
- description
- Primary analysis was performed two years early as per IDMC recommendation and the exploratory analysis of final DFS data at the prespecified maturity of approx. 50% was done in 2022. After the final DFS data analysis and until the final OS analysis, only limited data were collected: subsequent anti-cancer treatment, survival status and limited safety data. The AZ7550 metabolite samples were not analyzed after Mar 2019, so the ratio of metabolite to AZD9291 was not available for calculation.
- point Of Contact
- ClinicalTrialTransparency@astrazeneca.com
- organization
- AstraZeneca AB
- phone
- +447920183730
- title
- Global Clinical Leader
Complete source fields
- certain Agreement
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- limitations And Caveats
- description
- Primary analysis was performed two years early as per IDMC recommendation and the exploratory analysis of final DFS data at the prespecified maturity of approx. 50% was done in 2022. After the final DFS data analysis and until the final OS analysis, only limited data were collected: subsequent anti-cancer treatment, survival status and limited safety data. The AZ7550 metabolite samples were not analyzed after Mar 2019, so the ratio of metabolite to AZD9291 was not available for calculation.
- point Of Contact
- ClinicalTrialTransparency@astrazeneca.com
- organization
- AstraZeneca AB
- phone
- +447920183730
- title
- Global Clinical Leader
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice